Skip to content

Intravenous Dexamethasone for Preventing Postoperative Nausea and/or Vomiting in Total Abdominal Hysterectomy: A randomized double-blinded, placebo-controlled trial

Intravenous Dexamethasone for Preventing Postoperative Nausea and/or Vomiting in Total Abdominal Hysterectomy: A randomized double-blinded, placebo-controlled trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240416002
Enrollment
89
Registered
2024-04-16
Start date
2022-09-12
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants who diagnose with benign gynecologic conditions and scheduled for total abdominal hysterectomy with or without adnexal surgery. Postoperative nausea and vomiting, PONV, dexamethasone, hysterectomy

Interventions

Two hours after the operation, the ward nurse opened the randomization list, which contained 2 ml of dexamethasone or normal saline, identical in appearance. The dexamethasone group received 2 ml (8 m
2 ml of dexamethasone

Sponsors

Khon Kaen Hospital
Lead Sponsor
Khon Kaen Hospital
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants were diagnosed with benign gynecologic conditions and scheduled for total abdominal hysterectomy with or without adnexal surgery.

Exclusion criteria

Exclusion criteria: 1.Had a known hypersensitivity to dexamethasone 2. Had conditions that might influence gastrointestinal motility (including previous bowel surgery, previous abdominal irradiation, chronic constipation, pancreatitis, peritonitis, hypothyroidism, and chronic use of drugs that impact intestinal peristalsis 3. Had underlying diabetes mellitus who got poor glycemic control 4. Were immunocompromised (tuberculosis, HIV Infection) 5. Experienced an intraoperative blood loss of more than 1,000 ml or blood loss that required blood transfusion.

Design outcomes

Primary

MeasureTime frame
Incidence of PONV within 24 hours at 24 hours after receiving the intervention Percent

Secondary

MeasureTime frame
Additional Drug Requirements within 24 hours after receiving intervention Percent,Side effects of dexamethasone within 24 hours after receiving intervention Percent,Postoperative pain score at 24 hours after receiving intervention Mean,This length of hospital stay After participants were discharge from hospital Mean

Countries

Thailand

Contacts

Public ContactKanyawee Suhongsa

Khon Kaen Hospital

Kanyawee.suh@gmail.com0809432310

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026